^
    Back
    Association details:
    Biomarker:PIK3CA E542K
    Cancer:Squamous Cell Carcinoma of Head and Neck
    Drug:taselisib (GDC-0032) (PIK3CA inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Clin Cancer Res
    Title:

    Taselisib (GDC-0032), a Potent ß-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations

    Excerpt:
    We also saw superior activity with transient administration of GDC-0032 during radiation in a HPV+ PIK3CAE545K patientderived xenograft model (Supplementary Fig. S11). These data also suggest that both mutations (E542K in the helical domain and H1047R in the kinase domain) are functionally active in HNSCC.
    DOI:
    10.1158/1078-0432.CCR-15-2225